Skip to content
HowShorted

Ginkgo Bioworks Holdings, Inc. short interest in 2022

In 2022, Ginkgo Bioworks Holdings, Inc.'s disclosed short interest ran from 4.83% of shares outstanding on 14 Jan 2022 to 6.51% on 30 Dec 2022, a change of +1.68 percentage points. The year's high was 10.51% on 15 Sep 2022 and its low 4.83% on 14 Jan 2022, averaging 7.02% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.47 days on 28 Feb 2022. Full history: Ginkgo Bioworks Holdings, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Ginkgo Bioworks Holdings, Inc. in 2022

2022 in figures

Start of year
4.83% (14 Jan 2022)
End of year
6.51% (30 Dec 2022)
Change
+1.68 pp
High
10.51% (15 Sep 2022)
Low
4.83% (14 Jan 2022)
Average
7.02%
Highest days to cover
9.47 (28 Feb 2022)
SEC filings marked
9

Every report in 2022

Ginkgo Bioworks Holdings, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20224.83%6.49results (8-K)
31 Jan 20226.29%6.40
15 Feb 20225.71%6.59
28 Feb 20225.80%9.47
15 Mar 20225.96%7.27
31 Mar 20225.04%2.43results (8-K), 10-K filed
14 Apr 20225.52%3.68
29 Apr 20226.29%5.27
13 May 20226.09%4.32
31 May 20227.25%5.3210-Q filed, results (8-K)
15 Jun 20226.19%4.78
30 Jun 20227.57%4.43
15 Jul 20228.14%6.63
29 Jul 20228.46%9.33
15 Aug 20228.08%4.1410-Q filed, results (8-K)
31 Aug 202210.03%6.20
15 Sep 202210.51%8.96
30 Sep 20229.60%6.44
14 Oct 20228.76%6.38
31 Oct 20227.52%5.31
15 Nov 20226.41%5.0810-Q filed, results (8-K)
30 Nov 20226.11%4.01
15 Dec 20225.89%5.31
30 Dec 20226.51%5.48

See also: Ginkgo Bioworks Holdings, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.